WAM
KLRS

WealthTrust Asset Management’s Kalaris Therapeutics KLRS Stock Holding History

WealthTrust Asset Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.1K Buy
20,416
+8,000
+64% +$41.6K 0.05% 108
2026
Q1 		$71.6K Buy
+12,416
New +$110K 0.04% 96

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WealthTrust Asset Management's KLRS Position: Q2 2026 in Review

WealthTrust Asset Management increased its Kalaris Therapeutics (KLRS) stake by 64% in Q2 2026, buying an estimated $41.6K and bringing the position to 20,416 shares worth $83.1K. The position accounts for 0.05% of the portfolio, ranked #108.

WealthTrust Asset Management first reported a position in KLRS in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • WealthTrust Asset Management held 20,416 shares of Kalaris Therapeutics worth $83.1K as of Q2 2026.
  • WealthTrust Asset Management bought 8,000 Kalaris Therapeutics shares in Q2 2026, an estimated $41.6K.
  • Kalaris Therapeutics made up 0.05% of WealthTrust Asset Management's portfolio in Q2 2026, its #108 holding.
  • WealthTrust Asset Management first reported a position in Kalaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on WealthTrust Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.